Citations

Clear

3042 citation(s) found for "Kumar, S".

Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s Disease
Orr, Miranda E. , Garbarino, Valentina R. , Palavicini, Juan Pablo , Melendez, Justin , Barthélemy, Nicolas R. , He, Yingxin , Kautz, Tiffany F. , Mathews, Julia, Zhang, Bin , Saliba, Afaf, Ragi, Nagarjunachary, Craft, Suzanne , Petersen, Ronald C. , Espíndola‐Netto, Jair Machado , Xue, Ailing, Kirkland, James L. , Salardini, Arash , Musi, Nicolas , Gonzales, Mitzi M. , Palavicini, Juan Pablo , Melendez, Justin , Barthélemy, Nicolas R , He, Yingxin , Xu, Peng , Saliba, Afaf , Petersen, Ronald C , Espindola-Netto, Jair Machado, Tchkonia, Tamara, Kirkland, James L , Seshadri, Sudha , Bateman, Randall J , Orr, Miranda E , Gonzales, Mitzi , Garbarino, Valentina, Kautz, Tiffany, Lopez-Cruzan, Marisa, Mathews, Julia, Zhang, Bin, Ragi, Nagarjunachary, Sharma, Kumar, Craft, Suzanne, Espindola-Netto, Jair, Xue, Ailing, Tchkonia, Tamara, Salardini, Arash, Musi, Nicolas, Gonzales, Mitzi

Mayo Clinic

No container title available | March 8, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3994894/v1 | PMID 38496619 Get It

Abstract Senescent cell accumulation contributes to the progression of age-related disorders including Alzheimer’s disease (AD). Clinical trials evaluating senolytics, drugs that clear senescent cells, are underway, but lack standardized outcome measures. Our team recently published data from the first open-label trial to evaluate senolytics (dasatinib plus quercetin) in AD. After 12-weeks of intermittent treatment, we reported brain exposure to dasatinib, favorable safety and tolerability, and modest post-treatment changes in cerebrospinal fluid (CSF) inflammatory and AD biomarkers using commercially available assays. Herein, we present more comprehensive exploratory analyses of senolytic associated changes in AD relevant proteins, metabolites, lipids, and transcripts measured across blood, CSF, and urine. These analyses included mass spectrometry for precise quantification of amyloid beta (Aß) and tau in CSF; immunoassays to assess senescence associated secretory factors in plasma, CSF, and urine; mass spectrometry analysis of urinary metabolites and lipids in blood and CSF; and transcriptomic analyses relevant to chronic stress measured in peripheral blood cells. Levels of Aß and tau species remained stable. Targeted cytokine and chemokine analyses revealed treatment-associated increases in inflammatory plasma fractalkine and MMP-7 and CSF IL-6. Urinary metabolites remained unchanged. Modest treatment-associated lipid profile changes suggestive of decreased inflammation were observed both peripherally and centrally. Blood transcriptomic analysis indicated downregulation of inflammatory genes including FOS, FOSB, IL1β, IL8, JUN, JUNB, PTGS2. These data provide a foundation for developing standardized outcome measures across senolytic studies and indicate distinct biofluid-specific signatures that will require validation in future studies. ClinicalTrials.gov: NCT04063124.
Precision Oncology in Hematological Malignancies: Takeaways from the 2023 Precision Oncology Summit
Khan, Abdul Moiz , Abuali, Inas , Abrams, Hannah R. , Wieduwilt, Matthew J. , Nowakowski, Grzegorz S. , Kumar, Shaji , Larkin, Karilyn , Riaño, Ivy

Mayo Clinic

International Journal of Cancer Care and Delivery | March 6, 2024 | Volume: 4 | Issue: 1 | Pages: No page available

10.53876/001c.94432 Get It

The 2023 Precision Oncology Summit was organized by Binaytara foundation in San Francisco on October 7 th and 8 th . The conference’s theme was the advances in precision oncology and future directions to move away from a one-size-fits-all model to improve outcomes. This manuscript outlines the proceedings of the hematology-focused session during the conference.
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Ghobrial, Irene M. , Kumar, Shaji , Mateos, María‐Victoria , Bergsagel, P. Leif , Chesi, Marta , Dhodapkar, Madhav V. , Getz, Gad , Manier, Salomon , Nuvolone, Mario , O’Donnell, Elizabeth , Sklavenitis‐Pistofidis, Romanos , Sperling, Adam S. , Vassiliou, George S. , Munshi, Nikhil C. , Bergsagel, P. Leif , Gormley, Nicole , Kumar, Shaji K , Mateos, María-Victoria , Chesi, Marta , Dhodapkar, Madhav V , Getz, Gad , Kastritis, Efstathios , Kristinsson, Sigurdur Y , Martinez-Climent, Jose Angel , Manier, Salomon , Marinac, Catherine R , Maura, Francesco , Morgan, Gareth J , Davies, Faith E , Nadeem, Omar , Nuvolone, Mario , Paiva, Bruno , O'Donnell, Elizabeth , Prosper, Felipe , Shah, Urvi A , Sklavenitis-Pistofidis, Romanos , Sperling, Adam S , Munshi, Nikhil C , Castle, Philip E , Anderson, Kenneth C , San-Miguel, Jesus , Ghobrial, Irene M , Gormley, Nicole , Dispenzieri, Angela , Fonseca, Rafaël , Kastritis, Efstathios , Martinez‐Climent, José A. , Marinac, Catherine R. , Maura, Francesco , Morgan, Gareth J. , Davies, Faith E. , Nadeem, Omar , Paiva, Bruno , Prósper, Felipe , Shah, Urvi A. , Anderson, Kenneth C. , Miguel, Jesús F. San

Mayo Clinic

Blood Cancer Discovery | March 5, 2024 | Volume: 5 | Issue: 3 | Pages: 146-152

10.1158/2643-3230.bcd-24-0022 | PMID 38441243 Get It

Summary: While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment.
(220) Sexual Dysfunction in Krabbe Disease Patients - A Scoping Review
Sansoni, G Azevedo, Meier, Alexandra, Negris, Olivia , Thompson, B. Taylor , Bhagudas, Sarah, Pandey, Sanjeev Kumar , Kapoor, Seema , Meier, A, Thompson, B, Pandey, S, Jain, Shruti , Kapoor, S

Mayo Clinic

The Journal of Sexual Medicine | March 5, 2024 | Volume: 21 | Issue: Supplement_2 | Pages: No page available

10.1093/jsxmed/qdae002.197 Get It

Abstract Introduction Krabbe Disease (KD) or globoid cell leukodystrophy is a rare autosomal recessive lysosomal storage disorder affecting approximately 1 in 100,000 people worldwide. GALC gene mutations associated with KD involve a galactosylceramidase deficiency, which damages the oligodendrocytes and Schwann cells. Therefore, nervous system demyelination is a hallmark of KD. While only a few infants survive beyond two years in early-onset Krabbe disease, patients with late-onset Krabbe Disease exhibit a milder phenotype and longer life expectancy. Late-onset KD symptoms include progressive muscle weakness and stiffness, developmental regression, behavioral changes, dementia, hearing loss, vision problems, and seizures. Only a few cases of sexual dysfunction associated with KD have been reported in literature but they highlight the wide-ranging impact of this condition on young adults and adults. Objective This review aims to examine sexual dysfunction in KD, as reported in literature. We employ a broad definition of sexual dysfunction (erectile dysfunction, dyspareunia, orgasmic disorder, muscle weakness, etc.) and its incidence in both sexes with KD. A comprehensive review of this topic has not yet been conducted, and we offer here preliminary information for healthcare providers when addressing sexual concerns in patients with lysosomal storage disorders. Methods A literature search was conducted by two separate investigators who independently screened studies and abstracted data. Data sources included peer reviewed publications from the following databases: PubMed, Scopus, Web of Science, EMBASE, Cochrane, Google Scholar and Clinical trials.gov. There were no restrictions on language nor date of publication. The search algorithm utilized to generate the review list was: (Globoid cell leukodystrophy OR Galactosylcerebrosidase deficiency OR Galactosylceramidase deficiency OR Krabbe disease OR Late-onset Krabbe disease OR GALC mutation). Results were further filtered by article type, restricting articles to Case Reports, Clinical Trials, Reviews, and Systematic Reviews. Results were then screened for reports containing data on sexual dysfunction in patients with KD. Results A total of four case reports and one review paper contained reports of sexual dysfunction in KD patients. All cases involved late-onset Krabbe disease, characterized by a milder and more insidious presentation. Genitourinary symptoms reported included urinary incontinence (N=3) and erectile dysfunction (N=2), however, there were no reports (N=0) of symptoms related to female sexual dysfunction. Other symptoms commonly reported in late-onset KD that might be linked to sexual function were ataxia, spasticity and weakness of lower limbs (N=3), and sensory dysfunction due to peripheral neuropathy (N=4). Conclusions This pioneering review reveals that patients with KD experience symptoms of sexual dysfunction. While the rarity of KD makes it challenging to study it clinically, sexual dysfunction may be consistent with the known pathophysiology of late-onset KD. This review also highlights that sexual dysfunction in female patients with KD is an under-investigated component of the disease presentation. Future clinical research into this important comorbidity, especially in female patients where the literature is lacking, may improve the care of patients with KD. Disclosure No.
Abstract 282: Understanding Current Organizational Strategies to Support Physician Well‐Being in Stroke, Neurocritical Care, and Neurointerventional Practice
Kothari, Sachin , Castonguay, Alicia C. , Guerrero, Waldo R. , Asif, Kaiz , El‐Ghanem, Mohammad , Dumitrașcu, Oana , Ramos, Romario, Pandya, Dhruvil J., Kumar, Ashish , Abraham, Michael G.

Mayo Clinic

Stroke: Vascular and Interventional Neurology | March 5, 2024 | Volume: 3 | Issue: S2 | Pages: No page available

10.1161/svin.03.suppl_2.282 Get It

Introduction Burnout in medicine is an occupational hazard and has emerged as a pressing concern in recent years. Organizational changes can be impactful in countering burnout (1). The factors leading to burnout in medicine are multifaceted, encompassing organizational factors such as workload, inadequate support, and inefficient administrative systems. The purpose of this study is to investigate current organizational measures to support physician well‐being. This study was an initiative led by the SVIN wellness committee. Methods A 39‐question online survey investigating current organizational well‐being practices was distributed to physicians both nationally and internationally practicing stroke, neurocritical care, and interventional neurology. Data analysis was performed using Python, utilizing the libraries “pandas” and “sklearn”. Results This study analyzed burnout among 109 healthcare professionals, predominantly from the U.S. (93.6%) and Canada (6.4%). The majority were neurointerventional specialists (53.2%), aged 35‐44 years (52.3%), and male (62.4%). Burnout frequency was measured on a 0 (Never) to 4 (Every day) scale. Using a Random Forest model, the study identified key burnout predictors from questions, which covered organizational leadership, wellness resources, compensation, and workload. The most influential predictors were: adequacy of compensation relative to specialty, workload, and stress (17.7% importance); leadership accountability for workforce wellbeing (9.1%); and establishment of wellness or burnout as a critical metric (7.5%). Other factors included provision of wellness screenings (7.1%), and dedication of resources toward professional well‐being (4.9%). Conclusion The study identifies compensation, leadership accountability, and wellness resources as key predictors of burnout among healthcare professionals. These findings highlight the need for targeted organizational strategies to enhance physician well‐being and mitigate burnout. Further research is warranted to validate and expand upon these findings.
Abstract P06: Characterization of the Immune Tumor Microenvironment in a Diverse Cohort of Patients with Multiple Myeloma
Shivaram, Suganti, Tang, Hongwei , Yan, Huihuang , Tian, Shulan , Qin, Guyu , Anderson, Emilie, Bolarinwa, Abiola , Zepeda‐Mendoza, Cinthya , Dasari, Surendra , Kourelis, Taxiarchis , Kumar, Shaji , Bolarinwa, Abiola B , Tang, Hongwei, Sharma, Neeraj , Lehman, Stacey L. , Gomez, Felicia , Mitra, Amit , Baughn, Linda B.

Mayo Clinic

Blood Cancer Discovery | March 4, 2024 | Volume: 5 | Issue: 2_Supplement | Pages: P06-P06

10.1158/2643-3249.bcdsymp24-p06 Get It

Abstract Multiple myeloma (MM) is the most common blood cancer in African American (AA) individuals. AAs have an increased risk of developing Monoclonal Gammopathy of Undetermined Significance (MGUS) and MM compared to non-Hispanic White (NHW) individuals. While several studies have shown a pivotal role for the immune tumor microenvironment (iTME) in MM pathogenesis, the composition of the iTME in AAs with MM is under investigated. Viably frozen whole bone marrow (BM) aspirates from 128 individuals (53 AA and 75 NHW) with either MM (n=65), MGUS (n=28), smoldering MM (SMM, n=13), or healthy controls (n=22) were evaluated by single cell RNA-sequencing (scRNA-seq) or mass cytometry (CyTOF). We characterized 34 (14 AA and 20 NHW) by scRNA-seq and 94 (39 AA and 55 NHW) by CyTOF. CyTOF samples were stained with Maxpar Direct Immune Profiling Assay Kit (Fluidigm), acquired on a Helios mass cytometer and analyzed in Cytobank. Data were analyzed by logistic equivalent regression model with p<0.05 for significance. ScRNA-seq samples were processed as in Yao, 2022. Data were normalized using scvi-tools and clustered by Uniform manifold approximation and projection (UMAP). Differentially expressed markers between clusters were identified using Model-based Analysis of Single-cell Transcriptomics (MAST) in Seurat R package at FDR < 0.05 and log2 fold change > 0.55. ScRNA-seq of the CD45+ non-tumor lymphocytes revealed 17 immune populations (HSC, erythroblast, MDSC, GMP, CD1c+ DC, CD4+ and CD8+ T cell, CD14+ M1 macrophage, CD16+monocyte, monocyte, pDC, naïve B, pre-B, pro-B, memory B, NK/MAIT). CD3E/D+cells were clustered into naïve/central memory (CCR7+, LEF1+, SELL+), memory (GZMK+), effector (GZMB+, GZMH+, FGFBP2+), g/d (TRDC+), MAIT (SLC4A10+, KLRB1+) and IFN CD8+ T cells (IFIT1+, IFIT2+,IFIT3+). Disease progression was associated with increases in median CD4+ and CD8+ GZMK+ T cells, memory B cells and a reduction in all monocyte clusters. Within the diseased cohort in comparison to NHW patients, AA patients had increased CD3+ T cells (CD4 and CD8+) (AA 57.5% vs. NHW 44.3%) and a reduction in overall monocytes (AA 10.5% vs. 26.5%). These results were validated by CyTOF, which confirmed an increase in CD3+ T cells (AA 53.7% vs. NHW 35.7%, p<0.001) including increases in CD8+ (AA 7.0% vs. NHW 3.2%, p<0.05) and CD4+ terminal effector T cells (AA 5.7% vs. NHW 2.7%, p<0.05) and a reduction in monocytes (AA 18.3% vs. NHW 26.6%) among AAs. After adjusting for age and sex, AAs retained an increase in T cells (OR 1.59 (95%CI 1.2-2.01, p=0.00023)) and a reduction in monocytes (OR 0.88 (95%CI 0.78-1, p=0.045)). Despite the increase in CD8+ T cells in AA patients, we identified reduced GZMK+ T cells and reductions in exhaustion markers (TIGIT, LAG3, TOX) in CD8+ T cells in comparison to NHWs. Nevertheless, the distribution of the immune populations was similar between healthy AA and NHW individuals. Our multiomics approach to characterize the iTME identified significant differences among AA compared to NHW patients with MM. Citation Format: Suganti Shivaram, Hongwei Tang, Huihuang Yan, Shulan Tian, Guyu Qin, Emilie Anderson, Neeraj Sharma, Abiola Bolarinwa, Cinthya Zepeda-Mendoza, Stacey Lehman, Felicia Gomez, Amit Mitra, Surendra Dasari, Taxiarchis Kourelis, Shaji Kumar, Linda Baughn. Characterization of the Immune Tumor Microenvironment in a Diverse Cohort of Patients with Multiple Myeloma [abstract]. In: Proceedings of the Blood Cancer Discovery Symposium; 2024 Mar 4-6; Boston, MA. Philadelphia (PA): AACR; Blood Cancer Discov 2024;5(2_Suppl):Abstract nr P06.
Characteristics of and risk factors for COVID-19 breakthrough infections in idiopathic inflammatory myopathies: results from the COVAD study
Ravichandran, Naveen , Day, Jessica , Nune, Arvind , Nikiphorou, Elena , Tan, Ai Lyn , Velikova, Tsvetelina , Milchert, Marcin , Parodis, Ioannis , Kuwana, Masataka , Patel, Aarat , Wincup, Chris , Tehozol, Erick Adrian Zamora , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akarawatcharangura , Kibbi, Lina El , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Chinoy, Hector , Gupta, Latika, Group, COVAD Study, Ranjan, Rajiv , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , M, Manesh Manoj, Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Gaur, Prithvi Sanjeevkumar , Mamadapur, Mahabaleshwar , Ghodke, Akanksha, Kadam, Esha , Fazal, Zoha Zahid , Kardeş, Sinan , Yıldırım, Reşit, Maurier, F. , Meyer, Alain, Atzeni, Fabiola , Bocci, Elena Bartoloni, Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Grignaschi, Silvia, Giollo, Alessandro, Lini, Daniele , Alluno, Alessia, Loarce‐Martos, Jesus , Aránega, Raquel, Nakashima, Ran , Sato, Shinji , Kaneko, Yuko , Gono, Takahisa, Tomaras, Stylianos , Aharonov, Mr Or, Nagy‐Vincze, Melinda , Schrieber, Karen, bouchti, Pr Imane El, Baba, Zineb, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Ouma Devi , Palalane, Elisa, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane, Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Harifi, Ghita, Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, González, Raúl, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Argueta, Sandra, Quijivix, Daniel, Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, M, Roberto Morales Idania Escalante, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Agarwal, Vikas , Giollo, Alessandro , Gupta, Latika , Naveen, R , Day, Jessica , Nune, Arvind , Tan, Ai Lyn , Ziade, Nelly , Milchert, Marcin , Parodis, Ioannis , Gracia-Ramos, Abraham Edgar , Kuwana, Masataka , Knitza, Johannes , Pauling, John D , Wincup, Chris , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Lilleker, James B , Gheita, Tamer , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Agarwal, Vikas , Velikova, Tsvetelina , Zamora Tehozol, Erick Adrian , Dey, Dzifa , Caballero-Uribe, Carlo Vinicio , De Angelis, Rossella , Hoff, Leonardo Santos , Sen, Parikshit , Joshi, Mrudula , Saha, Sreoshy , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Jagtap, Kshitij , Gracia‐Ramos, Abraham Edgar , Cavagna, Lorenzo , Chen, Yi‐Ming , Makol, Ashima , Agarwal, Vishwesh , Pauling, John D , Barman, Bhupen , Rojas Serrano, Jorge , Torre, Ignacio García‐De La , Colunga-Pedraza, I. J. , Goo, Phonpen Akawatcharangura , Shumnalieva, Russka , Halabi, Hussein , Gheita, Tamer A. , Chatterjee, Tulika , Distler, Oliver , Saavedra, Miguel A , Aggarwal, Rohit , Group, COVAD Study, Singh, Yogesh Preet , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Giannini, Margherita , Campagne, Julien , Meyer, Alain , Papa, Nicoletta Del , Sambataro, Gianluca , Govoni, Marcello , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Venerito, Vincenzo , Andréoli, Laura , Iannone, Florenzo , Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Prieto‐González, Sergio , Yoshida, Akira , Kimura, Naoki, Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Griger, Zoltán , Hmamouchi, Ihsane , Emorinken, Airenakho , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Landon‐Cardinal, Océane , Arbeláez-Cortés, Álvaro , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , So, Ho , Ugarte‐Gil, Manuel F. , Fathi, Hanan Mohamed , Mohammed, Reem Hamdy A , Harifi, Ghita , Salinas, Rodrigo Nicolás Garcia

Mayo Clinic

Rheumatology | March 2, 2024 | Volume: 64 | Issue: 2 | Pages: 597-606

10.1093/rheumatology/keae128 | PMID 38430474 Get It

Abstract Objectives The objective of this study was to explore the prevalence, characteristics and risk factors of COVID-19 breakthrough infections (BIs) in idiopathic inflammatory myopathies (IIMs) using data from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods A validated patient self-reporting e-survey was circulated by the COVAD study group to collect data on COVID-19 infection and vaccination in 2022. BIs were defined as COVID-19 occurring ≥14 days after two vaccine doses. We compared BI characteristics and severity among patients with IIMs, patients with other autoimmune rheumatic and non-rheumatic diseases (AIRD, nrAID), and healthy controls (HCs). Multivariable Cox regression models were used to assess the risk factors for BI, severe BI ,and hospitalizations among patients with IIMs. Results Among the 9449 included responses, BIs occurred in 1447 respondents (15.3%). The median age was 44 years [interquartile range (IQR) 21], 77.4% were female, and 182 BIs (12.9%) occurred among the 1406 patients with IIMs. Multivariable Cox regression among the data for patients with IIMs showed increasing age to be a protective factor for BIs [hazard ratio (HR) = 0.98, 95% CI = 0.97–0.99], and HCQ and SSZ use were risk factors (HR = 1.81, 95% CI = 1.24–2.64, and HR = 3.79, 95% CI = 1.69–8.42, respectively). Glucocorticoid use was a risk factor for a severe BI (HR = 3.61, 95% CI = 1.09–11.8). Non-white ethnicity (HR = 2.61, 95% CI = 1.03–6.59) was a risk factor for hospitalization. Compared with other groups, patients with IIMs required more supplemental oxygen therapy (IIMs = 6.0% vs AIRDs = 1.8%, nrAIDs = 2.2% and HCs = 0.9%), intensive care unit admission (IIMs = 2.2% vs AIRDs = 0.6%, nrAIDs and HCs = 0%), advanced treatment with antiviral or monoclonal antibodies (IIMs = 34.1% vs AIRDs = 25.8%, nrAIDs = 14.6% and HCs = 12.8%) and had more hospitalization (IIMs = 7.7% vs AIRDs = 4.6%, nrAIDs = 1.1% and HCs = 1.5%). Conclusion Patients with IIMs are susceptible to severe COVID-19 BIs. Age and immunosuppressive treatments were related to the risk of BIs.
A small molecule MST1/2 inhibitor accelerates murine liver regeneration with improved survival in models of steatohepatitis
Watkins, Ryan , Gamo, Ana M. , Choi, Seung Hyuk , Kumar, Manoj , Buckarma, EeeLN H. , McCabe, Chantal E. , Tomlinson, Jennifer L. , Pereya, David, Lupše, Blaž , Geravandi, Shirin , Werneburg, Nathan W., Zhu, Siying , Li, Sijia, Yu, Shan , Surakattula, Murali, Baguley, Tyler D., Ardestani, Amin , Roland, Jason, Petrassi, Mike, Rogers, Nikki Lynn, Chatterjee, Arnab K. , Tremblay, Matthew S. , Smoot, Rory L. , Buckarma, EeeLN , McCabe, Chantal , Tomlinson, Jennifer , Wang, Chen , Starlinger, Patrick , Li, Sijia , Ardestani, Amin , Maedler, Kathrin , Joseph, Sean , Rogers, Nikki , Gores, Gregory J. , Chatterjee, Arnab , Shen, Weijun , Smoot, Rory L , Wang, Chen , Starlinger, Patrick , Nguyen-Tran, Vân T. B. , Gores, Gregory J.

Mayo Clinic

PNAS Nexus | March 1, 2024 | Volume: 3 | Issue: 3 | Pages: No page available

10.1093/pnasnexus/pgae096 | PMID 38528952 Get It

Abstract Dysfunctional liver regeneration following surgical resection remains a major cause of postoperative mortality and has no therapeutic options. Without targeted therapies, the current treatment paradigm relies on supportive therapy until homeostasis can be achieved. Pharmacologic acceleration of regeneration represents an alternative therapeutic avenue. Therefore, we aimed to generate a small molecule inhibitor that could accelerate liver regeneration with an emphasis on diseased models, which represent a significant portion of patients who require surgical resection and are often not studied. Utilizing a clinically approved small molecule inhibitor as a parent compound, standard medicinal chemistry approaches were utilized to generate a small molecule inhibitor targeting serine/threonine kinase 4/3 (MST1/2) with reduced off-target effects. This compound, mCLC846, was then applied to preclinical models of murine partial hepatectomy, which included models of diet-induced metabolic dysfunction-associated steatohepatitis (MASH). mCLC846 demonstrated on target inhibition of MST1/2 and reduced epidermal growth factor receptor inhibition. The inhibitory effects resulted in restored pancreatic beta-cell function and survival under diabetogenic conditions. Liver-specific cell-line exposure resulted in Yes-associated protein activation. Oral delivery of mCLC846 perioperatively resulted in accelerated murine liver regeneration and improved survival in diet-induced MASH models. Bulk transcriptional analysis of regenerating liver remnants suggested that mCLC846 enhanced the normal regenerative pathways and induced them following liver resection. Overall, pharmacological acceleration of liver regeneration with mCLC846 was feasible, had an acceptable therapeutic index, and provided a survival benefit in models of diet-induced MASH.
Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey
Yoshida, Akira , Maroufy, Vahed , Kuwana, Masataka , Shaharir, Syahrul Sazliyana , Kadam, Esha , Goo, Phonpen Akawatcharangura , Milchert, Marcin , Dey, Dzifa , Velikova, Tsvetelina , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Ziadé, Nelly , Kibbi, Lina El, Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Kardeş, Sinan , Vince, Melinda Nagy, Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal, Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Vaidya, Binit , Yıldırım, Reşit, Atzeni, Fabiola , Bocci, Elena Bartoloni, Orsolini, Giovanni , Angelis, Rossella De , Giollo, Alessandro, Fornaro, Marco, González, Raquel , Nakashima, Ran , Sato, Shinji , Kimura, Naoki , Kaneko, Yuko , Gono, Takahisa , Tomaras, Stylianos, Aharonov, Or, Bouchti, I. El , Baba, Zineb, Maurier, F. , Meyer, Alain, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, So, Ho, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Harifi, Ghita, Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, Nunez, Lilith Stange, Vergara, Cristián, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Mendoza, Idania Escalante, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Patel, Aarat , Tehozol, Erick Adrian Zamora , Chalico, Javier Merayo, Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Hasan, A T M Tanveer , Salim, Babur , Gupta, Latika , Kuwana, Masataka , Lilleker, James B , Day, Jessica , Milchert, Marcin , Dey, Dzifa , Gracia-Ramos, Abraham Edgar , Parodis, Ioannis , Tan, Ai Lyn , Nune, Arvind , Ziade, Nelly , Knitza, Johannes , Distler, Oliver , Chinoy, Hector , Aggarwal, Rohit , Gupta, Latika , Agarwal, Vikas , Velikova, Tsvetelina , Zamora Tehozol, Erick Adrian , Caballero-Uribe, Carlo Vinicio , Yoshida, Akira , De Angelis, Rossella , Li, Yuan , Makol, Ashima , Sen, Parikshit , Agarwal, Vishwesh , Day, Jessica , Chen, Yi‐Ming , Saha, Sreoshy , Gracia‐Ramos, Abraham Edgar , Nune, Arvind , Cavagna, Lorenzo , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study, Griger, Zoltán , Singh, Yogesh Preet , Ranjan, Rajiv , Jain, Avinash , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Ajmani, Sajal , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Sambataro, Gianluca , Govoni, Marcello , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Danieli, Maria Giovanna , Venerito, Vincenzo , Grignaschi, Silvia , Giollo, Alessandro, Alunno, Alessia , Iannone, Florenzo , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Loarce‐Martos, Jesus , Prieto‐González, Sergio , Gonzalez, Raquel Aranega, Tomaras, Stylianos , Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Baba, Zineb, Giannini, Margherita , Campagne, Julien , Meyer, Alain , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Arbeláez-Cortés, Álvaro , Cajas, Javier, Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Doskaliuk, Bohdana , Emorinken, Airenakho , Olaosebikan, Hakeem , Ugarte‐Gil, Manuel F. , Mohammed, Reem Hamdy A , Harifi, Ghita , Fuentes-Silva, Yurilís , Salinas, Rodrigo Nicolás Garcia , Andréoli, Laura , Lini, Daniele , Schreiber, Karen , Pauling, John D , Wincup, Chris , Barman, Bhupen , Rojas Serrano, Jorge , Torre, Ignacio García-De La, Colunga-Pedraza, I. J. , Shumnalieva, Russka , Hoff, Leonardo Santos , Halabi, Hussein , Gheita, Tamer A. , Chatterjee, Tulika

Mayo Clinic

Rheumatology Advances in Practice | February 29, 2024 | Volume: 8 | Issue: 2 | Pages: No page available

10.1093/rap/rkae028 | PMID 38524696 Get It

Abstract Objectives To investigate health-related quality of life in patients with idiopathic inflammatory myopathies (IIMs) compared with those with non-IIM autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs) and without autoimmune diseases (controls) using Patient-Reported Outcome Measurement Information System (PROMIS) instrument data obtained from the second COVID-19 vaccination in autoimmune disease (COVAD-2) e-survey database. Methods Demographics, diagnosis, comorbidities, disease activity, treatments and PROMIS instrument data were analysed. Primary outcomes were PROMIS Global Physical Health (GPH) and Global Mental Health (GMH) scores. Factors affecting GPH and GMH scores in IIMs were identified using multivariable regression analysis. Results We analysed responses from 1582 IIM, 4700 non-IIM AIRD and 545 nrAID patients and 3675 controls gathered through 23 May 2022. The median GPH scores were the lowest in IIM and non-IIM AIRD patients {13 [interquartile range (IQR) 10–15] IIMs vs 13 [11–15] non-IIM AIRDs vs 15 [13–17] nrAIDs vs 17 [15–18] controls, P < 0.001}. The median GMH scores in IIM patients were also significantly lower compared with those without autoimmune diseases [13 (IQR 10–15) IIMs vs 15 (13–17) controls, P < 0.001]. Inclusion body myositis, comorbidities, active disease and glucocorticoid use were the determinants of lower GPH scores, whereas overlap myositis, interstitial lung disease, depression, active disease, lower PROMIS Physical Function 10a and higher PROMIS Fatigue 4a scores were associated with lower GMH scores in IIM patients. Conclusion Both physical and mental health are significantly impaired in IIM patients, particularly in those with comorbidities and increased fatigue, emphasizing the importance of patient-reported experiences and optimized multidisciplinary care to enhance well-being in people with IIMs.
Caenorhabditis elegans model for in vivo screening of human gut microbiota mediated colonization and colonization resistance against Clostridioides difficile
Ambat, Achuthan , Valappil, Vishnu Thayyil, Harnvoravongchai, Phurt , Mishra, Shalabh Kumar , Gupta, Sushim, Ramachandran, Akhilesh, Kashyap, Purna , Scaria, Joy , Valappil, Vishnu Thayil, Ghimire, Sudeep , Pillai, Viju Vijayan , Gupta, Sushim, Ramachandran, Akhilesh

Mayo Clinic

No container title available | February 28, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2024.02.27.582212 Get It

Abstract The conventional bottom-up approach to probing the human gut microbiome’s link with hosts in germ-free models is hampered by considerable costs and time. To address this, our study introduces the nematode Caenorhabditis elegans as an innovative high-throughput model for exploring the gut microbiome’s impact on functional phenotypes. Traditionally, C. elegans studies have used continuous feeding for bacterial administration, a method that is unsuitable for anaerobes. For the first time, we have standardized a protocol for colonizing C. elegans with human gut anaerobes. By screening a microbial culturomics library representing 70% of the gut microbiome’s functional capacity, we showed successful colonization for 46% of the library. Functional phenotyping revealed that 5 of 10 strains, previously identified in vitro as inhibiting C. difficile , also inhibited in vivo . Validation of a selected strain in a germ-free mouse model confirmed colonization resistance and an immune response consistent with findings in C. elegans , underscoring the model’s translational potential.